I hope you make a speedy recovery, I'm still waiting for the braces they said should help been three weeks and still haven't heard from the therapy clinic. Good docking
“Spilling his whiskey, another flavour for his shirt…eyeing up the backend of the best thing he’d seen all week when…”
Also if the wounds do not seem to heal contact your Hospital. There might be an infection below. Do not think " it will go away" with time. Cheers. Kph
"Older people" also have less blood flow making infections more difficult to heal...so as Kai says, don't ignore that shit. If a person takes a pro active role on their symptoms, they can live decades longer than those who leave things to chance. I'm reassured you have the Navy paying for this stuff...i want to be annoyed by you for many years to come OP.
It might be atrial fibrillation. When they "touch " your heart it might take months that the normal function resumes altogether.
Then you have had infarctions or it is cardiomyopathy, the latter usually having open coronaries. By-pass originally was invented when poor heart moving sections started moving normally again after a while after the operation.
Well it's happening. Received 5" of wet snow yesterday. Flurries today and if the wind lays low we'll have ice on the lake by next weekend.
Snow is like sex, you don't know when you're going to get any, how much you'll get, or whether this is the one that kills you.
We are used to snow but during the last 4 out of 6 winters we have had " black winter ". No snow in the southern Finland. The shops have been in trouble as nobody buys skis etc.
The artist Oskar Kokoschka reworked ancient myths to express his fears for humanity. Daisy Dunn explores the meaning of the remarkable Prometheus Triptych – and how it resonates today. This month, the re-opening of the Courtauld Gallery in London after a major three-year restoration sees one of the largest and most extraordinary of Kokoschka's works go back on display following an even longer hiatus. The Prometheus Saga or Prometheus Triptych consists of three canvases spanning more than eight metres in total filled with colourful but terrifying scenes of the apocalypse and eternal punishment, inspired by Biblical passages and Greek myth. Confined to storage for more than a decade, the paintings have now been given pride of place in the newly refurbished 20th-Century gallery within the building. The overlooked masterpiece warning of a Cold War apocalypse
I thought I'd stick this here. Brigham and Women's Hospital will test the safety and efficacy of a nasal vaccine aimed at preventing and slowing Alzheimer's disease, the Boston hospital announced Tuesday. The start of the small, Phase I clinical trial comes after nearly 20 years of research led by Howard L. Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at the hospital. The trial will include 16 participants between the ages of 60 and 85, all with early symptomatic Alzheimer's but otherwise generally healthy. They will receive two doses of the vaccine one week apart, the hospital said in a press release. The participants will enroll from the Ann Romney Center. Phase I clinical trial is designed to establish the safety and dosage for a potential new medication. If it goes well, a much larger trial would be needed to test its effectiveness. The vaccine uses a substance called Protollin, which stimulates the immune system. "Protollin is designed to activate white blood cells found in the lymph nodes on the sides and back of the neck to migrate to the brain and trigger clearance of beta amyloid plaques — one of the hallmarks of AD [Alzheimer's disease]," the hospital explains. It notes that Protollin has been found to be safe in other vaccines. The launch of the first human trial of a nasal vaccine for Alzheimer's is a remarkable milestone," said Weiner in the hospital's press release. "Over the last two decades, we've amassed preclinical evidence suggesting the potential of this nasal vaccine for AD. If clinical trials in humans show that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer's, and it could also be given early to help prevent Alzheimer's in people at risk." The researchers say they aim to "determine the safety and tolerability of the nasal vaccine" in the trial and observe how Protollin affects participants' immune response, including how it affects their white blood cells. The immune system plays a very important role in all neurologic diseases," Weiner added. "And it's exciting that after 20 years of preclinical work, we can finally take a key step forward toward clinical translation and conduct this landmark first human trial." "Research in this area has paved the way for us to pursue a whole new avenue for potentially treating not only AD, but also other neurodegenerative diseases," said Tanuja Chitnis, MD, professor of neurology at Brigham and Women's Hospital and principal investigator of the trial. I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical are responsible for developing, manufacturing and commercializing Protollin. Medical researchers around the world have been working for years to develop new drugs to treat or slow Alzheimer's, the most common cause of dementia, which affects an estimated 6 million Americans. But many of the experimental medications that once seemed promising in early studies have not panned out, leaving patients and their families with few good treatment options. In June, the FDA approved the first new drug for Alzheimer's in 20 years, Biogen's Aduhelm. However, the decision sparked controversy following warnings from independent advisers that the much-debated drug had not been shown to help slow the brain-destroying disease and carries the risk of serious side effects. First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital
My Dad had four brothers and four sisters, he and two of his brothers and two sisters died from it. So five out of a family of nine. Not good odds.